熊中奎 郎娟 王思本

    [摘要] 胶质母细胞瘤(GBM)的生物标志物在疾病诊断、疗效预测和预后等方面发挥重要作用。GBM的生物标志物有以下4类：经典标志物、循环标志物、基因标签和其他。鉴于GBM的高度侵袭性和复杂性，临床上迫切需要深入研究可用于预后和预测的非侵入性生物标志物，尤其是可用于早期诊断的标志物。

    [关键词] 胶质母细胞瘤;生物标志物;表皮生长因子受体变体Ⅲ;1p/19q共缺失;异柠檬酸脱氢酶突变;O6-甲基鸟嘌呤-DNA 甲基转移酶甲基化

    [中图分类号] R730? ? ? ? ? [文献标识码] A? ? ? ? ? [文章编号] 1673-7210(2020)02(a)-0055-04

    [Abstract] Biomarkers of Glioblastoma multiforme (GBM) plays an important role in disease diagnosis， efficacy prediction and prognosis. There are four types of biomarkers for GBM： classical biomarkers， circulating biomarkers， gene tags and others. In view of the high invasiveness and complexity of GBM， there is an urgent to conduct in-depth clinical studies on non-invasive biomarkers that can be used for prognosis and prediction， especially for early diagnosis.

    [Key words] Glioblastoma multiforme; Biomarker; Epidermal growth factor receptor variantⅢ; 1p/19q codeletion; Isocitrate dehydrogenase mutation; O6-methylguanine-DNA methyltransferase methylation

    膠质母细胞瘤(glioblastoma multiforme，GBM)，WHO Ⅳ级，是最常见且恶性程度最高的原发性颅内肿瘤，占胶质瘤的一半以上。GBM生长迅速，短期内进展。目前治疗模式包括外科手术、放射外科、外放疗、化疗、靶向治疗和生物治疗等 ......